Buy Rating Affirmed for Aquestive Therapeutics Amid Solid Finances and Promising Anaphylm™ Prospects

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Aquestive Therapeutics (AQST – Research Report), with a price target of $9.00.

Ram Selvaraju has given his Buy rating due to a combination of factors pertaining to Aquestive Therapeutics’ current financial position and future prospects. Notably, the company has secured a significant cash runway extending into 2026, following a successful equity financing transaction. This financial stability is critical as the company prepares for the potential pre-launch activities of its Anaphylm™ program. Despite reporting a net loss, Aquestive’s revenue aligns closely with forecasts and they provide guidance within expected ranges for the coming years. The firm’s controlled financial trajectory and clear guidance contribute to a positive outlook for the stock.

Additionally, the potential of Anaphylm™ to lead the epinephrine product market segment bolsters the recommendation. The product’s advantages, including a rapid onset of action demonstrated in clinical trials and a convenient route of administration, may give it a competitive edge upon FDA approval. The regulatory path for Anaphylm’s approval appears straightforward, with the completion of necessary studies expected soon, paving the way for a timely New Drug Application submission. These factors combined—the solid financial footing and the promising developments in Aquestive’s pipeline—underpin Selvaraju’s optimistic Buy rating for AQST.

Selvaraju covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Axsome Therapeutics, and Genmab. According to TipRanks, Selvaraju has an average return of 4.2% and a 35.05% success rate on recommended stocks.

In another report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $9.00 price target.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Aquestive Therapeutics (AQST) Company Description:

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm® technology. The firm also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.